AFP and hepatocellular carcinoma: The most widely used surveillance tool for HCC in the at-risk population is biannual ultrasonography, with or without alpha-fetoprotein (AFP) testing, owing to its noninvasive nature and robust evidence supporting its cost-effectiveness [2,23,26,27].